XERIS PHARMACEUTICALS INC
- CIK: 0001346302
- EIN: 20-3352427
- Business address: 180 NORTH LASALLE STREET, SUITE 1600, CHICAGO, Illinois, 60601
About XERIS PHARMACEUTICALS INC
XERIS PHARMACEUTICALS INC (CIK: 0001346302) is an American company incorporated in the state of Illinois. Head office is located at 180 NORTH LASALLE STREET, SUITE 1600, CHICAGO, Illinois, 60601. Work in the industry 2834 - (CF Office: Office of Life Sciences) PHARMACEUTICAL PREPARATIONS. XERIS PHARMACEUTICALS INC is a public company and trade via Over-The-Counter (OTC).Ownership
| Owner | Filings | Transaction Date | Type of Owner |
|---|---|---|---|
| Pieper Steven | 0001875714 | Jul-28-2021 | officer: See Remarks |
| Thierer Mark | 0001334925 | Sep-30-2019 | director |
| Hecht Beth | 0001652410 | Jan-01-2019 | officer: See Remarks |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 0001009258 | Jun-20-2018 | 10 percent owner, other: Possible Member of 10% Group |
| Deerfield Mgmt L.P. | 0001010823 | Jun-20-2018 | 10 percent owner, other: Possible Member of 10% Group |
| SHERMAN JEFFREY W | 0001230482 | Jun-20-2018 | director |
| PERSKY MARLA | 0001270354 | Jun-20-2018 | director |
| Deutsch Barry M. | 0001289407 | Jun-20-2018 | officer: Chief Financial Officer |
| Flynn James E | 0001352546 | Jun-20-2018 | 10 percent owner, other: Possible Member of 10% Group |
| Deerfield Special Situations Fund, L.P. | 0001354395 | Jun-20-2018 | 10 percent owner, other: Possible Member of 10% Group |
| RIGBY JONATHAN | 0001356227 | Jun-20-2018 | director |
| Redmile Group, LLC | 0001425738 | Jun-20-2018 | 10 percent owner |
| Schmid John P. | 0001478916 | Jun-20-2018 | director |
| Edick Paul R | 0001531178 | Jun-20-2018 | director, officer: See Remarks |
| Shannon John Patrick Jr | 0001553595 | Jun-20-2018 | officer: See Remarks |
| Deerfield Private Design Fund III, L.P. | 0001603333 | Jun-20-2018 | 10 percent owner, other: Possible Member of 10% Group |
| Deerfield Mgmt III, L.P. | 0001610540 | Jun-20-2018 | 10 percent owner, other: Possible Member of 10% Group |
| BORMANN-KENNEDY BARBARA-JEAN ANNE | 0001635065 | Jun-20-2018 | director |
| Green Jeremy | 0001650527 | Jun-20-2018 | 10 percent owner |
| HALKUFF DAWN | 0001743658 | Jun-20-2018 | director |
| JOHNSON KENNETH ERLAND | 0001743774 | Jun-20-2018 | officer: See Remarks |
| PRESTRELSKI STEVEN | 0001744027 | Jun-20-2018 | officer: Chief Scientific Officer |
| Palmetto Partners, Ltd. | 0001744226 | Jun-20-2018 | 10 percent owner |
| Palmetto Partners 2014, LP | 0001744227 | Jun-20-2018 | 10 percent owner |
| Palmetto Partners 2015, LP | 0001744228 | Jun-20-2018 | 10 percent owner |
Stock Chart
Coming soon!
Jobs
Coming soon!
Recent SEC Filings
Includes all SEC registration details as well as a list of all documents (S-1, Prospectus, Current Reports, 8-K, 10K, Annual Reports) filed by XERIS PHARMACEUTICALS INC
| Filings | Format | Description | Filed/Effective | File/Film Number |
|---|---|---|---|---|
| SC 13G/A | Document | Amendment to Schedule filed to report acquisition of beneficial ownership of 5% or more of a class of equity securities by passive investors and certain institutions Acc-no: 0001398344-22-003371 (34 Act) Size: 116 KB |
Feb-14-2022 | 22634977 |
| 15-12B | Document | Notice of termination of registration of a class of securities under Section 12(b) Acc-no: 0001193125-21-300050 (34 Act) Size: 11 KB |
Oct-15-2021 | 211326276 |
| EFFECT | Document | Acc-no: 9999999995-21-003793 (33 Act) Size: 1 KB | Oct-06-2021 | 211310973 |
| 4 | Document | Statement of changes in beneficial ownership of securities Acc-no: 0000899243-21-039260 ( Act) Size: 13 KB |
Oct-05-2021 | |
| 4 | Document | Statement of changes in beneficial ownership of securities Acc-no: 0000899243-21-039259 ( Act) Size: 13 KB |
Oct-05-2021 | |
| 4 | Document | Statement of changes in beneficial ownership of securities Acc-no: 0000899243-21-039257 ( Act) Size: 15 KB |
Oct-05-2021 | |
| 4 | Document | Statement of changes in beneficial ownership of securities Acc-no: 0000899243-21-039255 ( Act) Size: 13 KB |
Oct-05-2021 | |
| 4 | Document | Statement of changes in beneficial ownership of securities Acc-no: 0000899243-21-039254 ( Act) Size: 22 KB |
Oct-05-2021 | |
| 4 | Document | Statement of changes in beneficial ownership of securities Acc-no: 0000899243-21-039253 ( Act) Size: 20 KB |
Oct-05-2021 | |
| 4 | Document | Statement of changes in beneficial ownership of securities Acc-no: 0000899243-21-039249 ( Act) Size: 22 KB |
Oct-05-2021 | |
| 4 | Document | Statement of changes in beneficial ownership of securities Acc-no: 0000899243-21-039248 ( Act) Size: 21 KB |
Oct-05-2021 | |
| 4 | Document | Statement of changes in beneficial ownership of securities Acc-no: 0000899243-21-039246 ( Act) Size: 22 KB |
Oct-05-2021 | |
| 4 | Document | Statement of changes in beneficial ownership of securities Acc-no: 0000899243-21-039244 ( Act) Size: 13 KB |
Oct-05-2021 | |
| 4 | Document | Statement of changes in beneficial ownership of securities Acc-no: 0000899243-21-039242 ( Act) Size: 22 KB |
Oct-05-2021 | |
| 25-NSE | Document | Acc-no: 0001354457-21-001128 (34 Act) Size: 2 KB | Oct-05-2021 | 211307450 |
| POS AM | Document | Post-effective amendment to a registration statement that is not immediately effective upon filing Acc-no: 0001193125-21-292163 (33 Act) Size: 24 KB |
Oct-05-2021 | 211307216 |
| S-8 POS | Document | Post-effective amendment to a S-8 registration statement Acc-no: 0001193125-21-292157 (33 Act) Size: 22 KB |
Oct-05-2021 | 211307157 |
| S-8 POS | Document | Post-effective amendment to a S-8 registration statement Acc-no: 0001193125-21-292144 (33 Act) Size: 22 KB |
Oct-05-2021 | 211307060 |
| S-8 POS | Document | Post-effective amendment to a S-8 registration statement Acc-no: 0001193125-21-292123 (33 Act) Size: 22 KB |
Oct-05-2021 | 211306978 |
| S-8 POS | Document | Post-effective amendment to a S-8 registration statement Acc-no: 0001193125-21-292118 (33 Act) Size: 22 KB |
Oct-05-2021 | 211306939 |
Recent 20 filings. View all XERIS PHARMACEUTICALS INC filings
Reviews
Jean Bishop
Very good communication and delivery made within the timeframe I was advised of
Samuel Ejimofor
It's being easier working on the website. And I recommend, it's a great website
Catherine
Thanks I look forward to using the product to improve my skin tone
Frequently Asked Questions
Tags:
- XERIS PHARMACEUTICALS INC overview
- XERIS PHARMACEUTICALS INC job
- XERIS PHARMACEUTICALS INC stock
- XERIS PHARMACEUTICALS INC ownership
- XERIS PHARMACEUTICALS INC CEO
- XERIS PHARMACEUTICALS INC documents
Disclaimer: The information on the Service is provided with the understanding that the Company is not herein engaged in rendering legal, accounting, tax, or other professional advice and services. As such, it should not be used as a substitute for consultation with professional accounting, tax, legal or other competent advisers.
Orther Companies
Contineum Therapeutics, Inc.
Update: Mar 16, 2024
Cuprina Holdings (Cayman) LTD
Update: Mar 08, 2024
APRINOIA Therapeutics Inc.
Update: Jan 27, 2024
Zhengye Biotechnology Holding Ltd
Update: Jan 10, 2024
Alto Neuroscience, Inc.
Update: Nov 28, 2023
Mural Oncology plc
Update: Nov 02, 2023
Latest News
SEC Adopts Rules to Improve Clearing Agency Governance and Mitigate...
Charter Communications to Pay $25 Million Penalty for Unauthorized...
SEC Announces Enforcement Results for Fiscal Year 2023
SEC Charges Former Co-CEOs of Tech Start-Up Bitwise Industries...
SEC Charges Royal Bank of Canada with Internal Accounting Controls...
SEC Charges President/CCO of Prophecy Asset Management Advisory...
SEC Adopts Rules for the Registration and Regulation of Security-Based...
SEC Charges Crypto Company SafeMoon and its Executive Team for...
© 2022 